Omontys administration: intravenous vs subcutaneous
From the Reuters article: "The adverse reactions were observed only in cases of intravenous use of Omontys. Omontys was approved last March for intravenous and subcutaneous administration to treat anemia in adult chronic kidney disease patients undergoing dialysis."
What percentage of Omontys patients (if any) received the drug subcutaneously? What determines how the drug is to be administered? Is it possible Omontys could be re-introduced for subcutaneous use only?
Amgn recall for epogen in 2010 reason flakes in vial - but no fuss....affy - fresenius completed the trial to sign the supply contract and how come fda got recall on adverse reactions whereas ...........................fresenius still endrose that - trails were satisfactory !!!!!!!!!!